Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Pilot Trial Evaluating Maintenance Therapy With Lamivudine(Epivir) and Dolutegravir(Tivicay) in Human Immunodeficiency Virus 1 (HIV-1) Infected Patients Virologically Suppressed With Triple HAART - ANRS 167 Lamidol

Trial Profile

A Pilot Trial Evaluating Maintenance Therapy With Lamivudine(Epivir) and Dolutegravir(Tivicay) in Human Immunodeficiency Virus 1 (HIV-1) Infected Patients Virologically Suppressed With Triple HAART - ANRS 167 Lamidol

Status: Completed
Phase of Trial: Phase I/II

Latest Information Update: 06 Nov 2021

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Dolutegravir (Primary) ; Lamivudine (Primary)
  • Indications HIV-1 infections
  • Focus Therapeutic Use
  • Acronyms ANRS167 LAMIDOL
  • Most Recent Events

    • 21 Jul 2021 Results assessing the proportion of APOBEC3F/3G defective viruses in PBMC from ARV-treated patients with prolonged virological suppression, presented at the 11th International AIDS Society Conference on HIV Science
    • 11 Mar 2020 Results (n=96) assessing factors between drug concentration and body weights in HIV-1-infections patients were presented at the 27th Conference on Retroviruses and Opportunistic Infections
    • 24 Feb 2020 Results of pharmacovirological analysis describing plasma residual HIV viraemia, cellular HIV reservoir size, blood plasma drug concentrations and their male genital tract penetration during the maintenance dual therapy dolutegravir + lamivudine published in the Journal of Antimicrobial Chemotherapy
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with username/password or try via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Back to top